Data / Drug companies / Ascend Laboratories, LLC
Ascend Laboratories, LLC: 357 products in the FDA NDC directory, labeler code 67877
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ascend Laboratories, LLC (labeler code 67877) lists 357 products in the FDA National Drug Code Directory, covering 121 finished drugs by generic name. By type: 354 prescription drugs, 3 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 15, 2026.
The request: Watch Ascend Laboratories, LLC (FDA labeler code 67877): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67877
- Products in commercial distribution
- 357
- Packages
- 1,089
- Finished drugs by generic name
- 121
- Prescription products
- 354
- Over the counter products
- 0
- Controlled substance products
- Schedule II 12, Schedule III 5, Schedule IV 9, Schedule V 15
- Flagged as original packager
- 304 of 304 products that carry the flag
- Started marketing in the last 12 months
- 34
- Earliest marketing start
- December 23, 1985
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 350 | 98% |
| Authorized generics (NDA) | 3 | 0.8% |
| Drugs for further processing | 3 | 0.8% |
| New drug applications (NDA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 354 | 99.2% |
| Drugs for further processing | 3 | 0.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 98 | 27.5% |
| Tablet, film coated | 96 | 26.9% |
| Capsule | 47 | 13.2% |
| Tablet, film coated, extended release | 19 | 5.3% |
| Tablet, extended release | 15 | 4.2% |
| Solution | 10 | 2.8% |
| Capsule, delayed release | 9 | 2.5% |
| Kit | 9 | 2.5% |
| Powder, for suspension | 8 | 2.2% |
| Capsule, coated pellets | 6 | 1.7% |
| Tablet, delayed release | 5 | 1.4% |
| Capsule, extended release | 5 | 1.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Topiramate | 67877-796 | Capsule, extended release | Generic drugs (ANDA) | October 15, 2026 |
| Topiramate | 67877-795 | Capsule, extended release | Generic drugs (ANDA) | October 15, 2026 |
| Topiramate | 67877-794 | Capsule, extended release | Generic drugs (ANDA) | October 15, 2026 |
| Topiramate | 67877-793 | Capsule, extended release | Generic drugs (ANDA) | October 15, 2026 |
| Lidocaine | 67877-767 | Patch | Generic drugs (ANDA) | September 22, 2026 |
| Ibuprofen | 67877-739 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2026 |
| Ibuprofen | 67877-738 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2026 |
| Ibuprofen | 67877-737 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2026 |
| Tolvaptan | 67877-924 | Kit | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-923 | Kit | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-922 | Kit | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-921 | Kit | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-920 | Kit | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-919 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-918 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-917 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-916 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tolvaptan | 67877-915 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Buprenorphine and naloxone | 67877-607 | Tablet | Generic drugs (ANDA) | July 3, 2026 |
| Buprenorphine and naloxone | 67877-606 | Tablet | Generic drugs (ANDA) | July 3, 2026 |
| Mirabegron | 67877-890 | For suspension, extended release | Generic drugs (ANDA) | June 15, 2026 |
| Mycophenolic acid | 67877-929 | Tablet, delayed release | Generic drugs (ANDA) | April 21, 2026 |
| Mycophenolic acid | 67877-928 | Tablet, delayed release | Generic drugs (ANDA) | April 21, 2026 |
| Dapagliflozin and metformin hydrochloride | 67877-622 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and metformin hydrochloride | 67877-621 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.